Literature DB >> 19895918

CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII.

N Fratzl-Zelman1, R Morello, B Lee, F Rauch, F H Glorieux, B M Misof, K Klaushofer, P Roschger.   

Abstract

Cartilage-associated protein (CRTAP) is an essential cofactor for the proper post-translational chain modification and collagen folding. CRTAP mutations lead mice (Crtap-/- mice) and humans (OI type VII) to a severe/lethal osteochondrodystrophy; patients have fractures at birth, deformities of the lower extremities and impaired growth. The consequences of CRTAP deficiency on intrinsic bone material properties are still unknown. In the present study we evaluated bone quality based on quantitative backscattered electron imaging (qBEI) to assess bone mineralization density distribution (BMDD) in femurs from 12 weeks old Crtap-/- mice and transiliac bone biopsies from 4 children with hypomorphic mutations and having residual CRTAP expression. The analyses revealed in the bone matrix of Crtap-/- animals and OI type VII patients a significant increase in mean (CaMean) and most frequent mineral concentration (CaPeak) compared to wild-type littermates and control children, respectively. The heterogeneity of mineralization (CaWidth) was reduced in Crtap-/- mice but normal in OI type VII patients. The fraction of highly mineralized bone matrix (CaHigh) was remarkably increased in the patients: cancellous bone from 2.1 to 3.7 times and cortical bone from 7.6 to 25.5 times, associated with an increased persistence of primary bone. In conclusion, the BMDD data show that CRTAP deficiency results in a shift towards higher mineral content of the bone matrix similar to classical OI with collagen gene mutations. Our data further suggest altered mineralization kinetics resulting ultimately in an overall elevated tissue mineralization density. Finally, in OI type VII patients the increased portion of primary bone is most likely reflecting a disturbed bone development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895918      PMCID: PMC2825377          DOI: 10.1016/j.bone.2009.10.037

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  41 in total

1.  The mineralization density of iliac crest bone from children with osteogenesis imperfecta.

Authors:  A Boyde; R Travers; F H Glorieux; S J Jones
Journal:  Calcif Tissue Int       Date:  1999-03       Impact factor: 4.333

2.  Static and dynamic bone histomorphometry in children with osteogenesis imperfecta.

Authors:  F Rauch; R Travers; A M Parfitt; F H Glorieux
Journal:  Bone       Date:  2000-06       Impact factor: 4.398

3.  Cellular activity on the seven surfaces of iliac bone: a histomorphometric study in children and adolescents.

Authors:  Frank Rauch; Rose Travers; Francis H Glorieux
Journal:  J Bone Miner Res       Date:  2006-04-05       Impact factor: 6.741

Review 4.  The bone cell biology of osteogenesis imperfecta.

Authors:  N S Fedarko; U Vetter; P G Robey
Journal:  Connect Tissue Res       Date:  1995       Impact factor: 3.417

5.  The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging.

Authors:  S J Jones; F H Glorieux; R Travers; A Boyde
Journal:  Calcif Tissue Int       Date:  1999-01       Impact factor: 4.333

6.  Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.

Authors:  Markus Weber; Paul Roschger; Nadja Fratzl-Zelman; Thomas Schöberl; Frank Rauch; Francis H Glorieux; Peter Fratzl; Klaus Klaushofer
Journal:  Bone       Date:  2006-04-27       Impact factor: 4.398

7.  CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta.

Authors:  Roy Morello; Terry K Bertin; Yuqing Chen; John Hicks; Laura Tonachini; Massimiliano Monticone; Patrizio Castagnola; Frank Rauch; Francis H Glorieux; Janice Vranka; Hans Peter Bächinger; James M Pace; Ulrike Schwarze; Peter H Byers; MaryAnn Weis; Russell J Fernandes; David R Eyre; Zhenqiang Yao; Brendan F Boyce; Brendan Lee
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

8.  Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.

Authors:  Barbara M Misof; Paul Roschger; Todd Baldini; Cathleen L Raggio; Vivien Zraick; Leon Root; Adele L Boskey; Klaus Klaushofer; Peter Fratzl; Nancy P Camacho
Journal:  Bone       Date:  2005-01       Impact factor: 4.398

9.  Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim).

Authors:  B Grabner; W J Landis; P Roschger; S Rinnerthaler; H Peterlik; K Klaushofer; P Fratzl
Journal:  Bone       Date:  2001-11       Impact factor: 4.398

10.  Structural and cellular changes during bone growth in healthy children.

Authors:  A M Parfitt; R Travers; F Rauch; F H Glorieux
Journal:  Bone       Date:  2000-10       Impact factor: 4.398

View more
  26 in total

Review 1.  Bone mineralization: from tissue to crystal in normal and pathological contexts.

Authors:  Y Bala; D Farlay; G Boivin
Journal:  Osteoporos Int       Date:  2012-12-11       Impact factor: 4.507

Review 2.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

Review 3.  Bone composition: relationship to bone fragility and antiosteoporotic drug effects.

Authors:  Adele L Boskey
Journal:  Bonekey Rep       Date:  2013-12-04

4.  Studies of chain substitution caused sub-fibril level differences in stiffness and ultrastructure of wildtype and oim/oim collagen fibers using multifrequency-AFM and molecular modeling.

Authors:  Tao Li; Shu-Wei Chang; Naiara Rodriguez-Florez; Markus J Buehler; Sandra Shefelbine; Ming Dao; Kaiyang Zeng
Journal:  Biomaterials       Date:  2016-08-24       Impact factor: 12.479

5.  COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta.

Authors:  Katarina Lindahl; Aileen M Barnes; Nadja Fratzl-Zelman; Michael P Whyte; Theresa E Hefferan; Elena Makareeva; Marina Brusel; Michael J Yaszemski; Carl-Johan Rubin; Andreas Kindmark; Paul Roschger; Klaus Klaushofer; William H McAlister; Steven Mumm; Sergey Leikin; Efrat Kessler; Adele L Boskey; Osten Ljunggren; Joan C Marini
Journal:  Hum Mutat       Date:  2011-04-07       Impact factor: 4.878

6.  Validation of cortical bone mineral density distribution using micro-computed tomography.

Authors:  Maleeha Mashiatulla; Ryan D Ross; D Rick Sumner
Journal:  Bone       Date:  2017-03-29       Impact factor: 4.398

7.  Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.

Authors:  Ingo Grafe; Stefanie Alexander; Tao Yang; Caressa Lietman; Erica P Homan; Elda Munivez; Yuqing Chen; Ming Ming Jiang; Terry Bertin; Brian Dawson; Franklin Asuncion; Hua Zhu Ke; Michael S Ominsky; Brendan Lee
Journal:  J Bone Miner Res       Date:  2016-02-12       Impact factor: 6.741

Review 8.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

9.  Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes.

Authors:  Heike Weidner; Ulrike Baschant; Franziska Lademann; Maria G Ledesma Colunga; Ekaterina Balaian; Christine Hofbauer; Barbara M Misof; Paul Roschger; Stéphane Blouin; William G Richards; Uwe Platzbecker; Lorenz C Hofbauer; Martina Rauner
Journal:  JCI Insight       Date:  2020-08-06

10.  Comparison of bone tissue properties in mouse models with collagenous and non-collagenous genetic mutations using FTIRI.

Authors:  Rhima M Coleman; Laura Aguilera; Layla Quinones; Lyudamila Lukashova; Christophe Poirier; Adele Boskey
Journal:  Bone       Date:  2012-08-15       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.